1-20 of 31
venetoclax
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Clinical Trials & Observations
Luciano J. Costa, Faith E. Davies, Gregory P. Monohan, Tibor Kovacsovics, Nicholas Burwick, Andrzej Jakubowiak, Jonathan L. Kaufman, Wan-Jen Hong, Monique Dail, Ahmed Hamed Salem, Xiaoqing Yang, Abdullah A. Masud, Wijith Munasinghe, Jeremy A. Ross, Orlando F. Bueno, Shaji K. Kumar, Edward A. Stadtmauer
Journal: Blood Advances
Blood Adv (2021) 5 (19): 3748–3759.
https://doi.org/10.1182/bloodadvances.2020004146
Published: 2021
Includes: Supplemental data
Journal Articles

Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL

Kallesh D. Jayappa, Vicki L. Gordon, Christopher G. Morris, Briana Wilson, B. Dharmaveer Shetty, Konrad J. Cios, Puja C. Arora, Krista M. Isaac, Shekhar Saha, Timothy P. Bender, Michael E. Williams, Craig A. Portell, Michael J. Weber
Journal: Blood Advances
Blood Adv (2021) 5 (17): 3497–3510.
https://doi.org/10.1182/bloodadvances.2020003944
Published: 2021
Includes: Supplemental data
Journal Articles

The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1 + leukemia

Eileen Y. Hu, Priscilla Do, Swagata Goswami, Jessica Nunes, Chi-ling Chiang, Sara Elgamal, Ann M. Ventura, Carolyn Cheney, Kevan Zapolnik, Erich Williams, Rajeswaran Mani, Frank Frissora, Xiaokui Mo, Lorenz Waldmeier, Roger R. Beerli, Haiyong Peng, Christoph Rader, Meixiao Long, Ulf Grawunder, John C. Byrd, Natarajan Muthusamy
Journal: Blood Advances
Blood Adv (2021) 5 (16): 3152–3162.
https://doi.org/10.1182/bloodadvances.2020003276
Published: 2021
Includes: Supplemental data
Journal Articles

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Clinical Trials & Observations
Lucia Masarova, Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Naval G. Daver, Tapan M. Kadia, Helen T. Chifotides, Lingsha Zhou, Gautam Borthakur, Zeev Estrov, Marina Konopleva, Srdan Verstovsek
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2156–2164.
https://doi.org/10.1182/bloodadvances.2020003934
Published: 2021
Includes: Supplemental data
Journal Articles

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Clinical Trials & Observations
Curtis A. Lachowiez, Sanam Loghavi, Ken Furudate, Guillermo Montalban-Bravo, Abhishek Maiti, Tapan Kadia, Naval Daver, Gautam Borthakur, Naveen Pemmaraju, Koji Sasaki, Yesid Alvarado, Musa Yilmaz, Nicholas J. Short, Kelly Chien, Maro Ohanian, Sherry Pierce, Keyur P. Patel, Elias Jabbour, Farhad Ravandi, Hagop M. Kantarjian, Guillermo Garcia-Manero, Koichi Takahashi, Marina Y. Konopleva, Courtney D. DiNardo
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2173–2183.
https://doi.org/10.1182/bloodadvances.2020004173
Published: 2021
Includes: Supplemental data
Journal Articles

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Clinical Trials & Observations
Abhishek Maiti, Courtney D. DiNardo, Sa A. Wang, Jeffrey Jorgensen, Tapan M. Kadia, Naval G. Daver, Nicholas J. Short, Musa Yilmaz, Naveen Pemmaraju, Gautam Borthakur, Prithviraj Bose, Ghayas C. Issa, Alessandra Ferrajoli, Elias J. Jabbour, Nitin Jain, Guillermo Garcia-Manero, Maro Ohanian, Koichi Takahashi, Guillermo Montalban-Bravo, Lucia Masarova, Jan A. Burger, Philip A. Thompson, Srdan Verstovsek, Koji Sasaki, Michael Andreeff, Caitlin R. Rausch, Kathryn S. Montalbano, Sherry Pierce, Wei Qiao, Jing Ning, Hagop M. Kantarjian, Marina Y. Konopleva, Farhad Ravandi
Journal: Blood Advances
Blood Adv (2021) 5 (7): 1876–1883.
https://doi.org/10.1182/bloodadvances.2020003717
Published: 2021
Includes: Supplemental data
Journal Articles

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Clinical Trials & Observations
Maximilian Stahl, Kamal Menghrajani, Andriy Derkach, Alexander Chan, Wenbin Xiao, Jacob Glass, Amber C. King, Anthony F. Daniyan, Christopher Famulare, Bernadette M. Cuello, Troy Z. Horvat, Omar Abdel-Wahab, Ross L. Levine, Aaron D. Viny, Eytan M. Stein, Sheng F. Cai, Mikhail Roshal, Martin S. Tallman, Aaron D. Goldberg
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1552–1564.
https://doi.org/10.1182/bloodadvances.2020003734
Published: 2021
Includes: Supplemental data
Journal Articles

Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia

Kishan K. Patel, Amer M. Zeidan, Rory M. Shallis, Thomas Prebet, Nikolai Podoltsev, Scott F. Huntington
Journal: Blood Advances
Blood Adv (2021) 5 (4): 994–1002.
https://doi.org/10.1182/bloodadvances.2020003902
Published: 2021
Includes: Supplemental data
Journal Articles

Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax

Blake S. Moses, Samantha McCullough, Jennifer M. Fox, Bryan T. Mott, Søren M. Bentzen, MinJung Kim, Jeffrey W. Tyner, Rena G. Lapidus, Ashkan Emadi, Michelle A. Rudek, Tami J. Kingsbury, Curt I. Civin
Journal: Blood Advances
Blood Adv (2021) 5 (3): 711–724.
https://doi.org/10.1182/bloodadvances.2020003429
Published: 2021
Includes: Supplemental data
Journal Articles

PI3Kδ inhibition reshapes follicular lymphoma–immune microenvironment cross talk and unleashes the activity of venetoclax

Neus Serrat, Martina Guerrero-Hernández, Alba Matas-Céspedes, Anella Yahiaoui, Juan G. Valero, Ferran Nadeu, Guillem Clot, Miriam Di Re, Marc Corbera-Bellalta, Laura Magnano, Alfredo Rivas-Delgado, Anna Enjuanes, Silvia Beà, Maria C. Cid, Elías Campo, Joan Montero, Daniel J. Hodson, Armando López-Guillermo, Dolors Colomer, Stacey Tannheimer, Patricia Pérez-Galán
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4217–4231.
https://doi.org/10.1182/bloodadvances.2020001584
Published: 2020
Includes: Supplemental data
Journal Articles

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Lindsey E. Roeker, Peter Dreger, Jennifer R. Brown, Oscar B. Lahoud, Toby A. Eyre, Danielle M. Brander, Alan Skarbnik, Catherine C. Coombs, Haesook T. Kim, Matthew Davids, Steven T. Manchini, Gemlyn George, Nirav Shah, Timothy J. Voorhees, Kim H. Orchard, Harriet S. Walter, Arvind K. Arumainathan, Andrea Sitlinger, Jae H. Park, Mark B. Geyer, Andrew D. Zelenetz, Craig S. Sauter, Sergio A. Giralt, Miguel-Angel Perales, Anthony R. Mato
Journal: Blood Advances
Blood Adv (2020) 4 (16): 3977–3989.
https://doi.org/10.1182/bloodadvances.2020001956
Published: 2020
Journal Articles

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression

Thomas E. C. Cummin, Kerry L. Cox, Tom D. Murray, Anna H. Turaj, Lisa Dunning, Vikki L. English, Rachel Fell, Graham Packham, Yan Ma, Ben Powell, Peter W. M. Johnson, Mark S. Cragg, Matthew J. Carter
Journal: Blood Advances
Blood Adv (2020) 4 (14): 3316–3328.
https://doi.org/10.1182/bloodadvances.2020002231
Published: 2020
Includes: Supplemental data
Journal Articles

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Clinical Trials & Observations
Brian J. Ball, Christopher A. Famulare, Eytan M. Stein, Martin S. Tallman, Andriy Derkach, Mikhail Roshal, Saar I. Gill, Benjamin M. Manning, Jamie Koprivnikar, James McCloskey, Rebecca Testi, Thomas Prebet, Najla H. Al Ali, Eric Padron, David A. Sallman, Rami S. Komrokji, Aaron D. Goldberg
Journal: Blood Advances
Blood Adv (2020) 4 (13): 2866–2870.
https://doi.org/10.1182/bloodadvances.2020001482
Published: 2020
Includes: Supplemental data
Journal Articles

Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms

Clinical Trials & Observations
Michael A. Spinner, Alexey Aleshin, Marianne T. Santaguida, Steven A. Schaffert, James L. Zehnder, A. Scott Patterson, Christos Gekas, Diane Heiser, Peter L. Greenberg
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2768–2778.
https://doi.org/10.1182/bloodadvances.2020001934
Published: 2020
Includes: Supplemental data
Journal Articles

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Clinical Trials & Observations
Curtis A. Lachowiez, Sanam Loghavi, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Naveen Pemmaraju, Kiran Naqvi, Yesid Alvarado, Musa Yilmaz, Nicholas Short, Maro Ohanian, Sherry R. Pierce, Keyur P. Patel, Wei Qiao, Jing Ning, Koji Sasaki, Koichi Takahashi, Elias Jabbour, Michael Andreeff, Farhad Ravandi, Hagop M. Kantarjian, Marina Konopleva, Courtney D. DiNardo
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1311–1320.
https://doi.org/10.1182/bloodadvances.2019001267
Published: 2020
Includes: Supplemental data
Journal Articles

Pollyea DA, Amaya M, Strati P, Konopleva MY. Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019;3(24):4326-4335.

Journal: Blood Advances
Blood Adv (2020) 4 (6): 1020.
https://doi.org/10.1182/bloodadvances.2020001769
Published: 2020
Journal Articles

Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models

Chiara Tarantelli, Martin Lange, Eugenio Gaudio, Luciano Cascione, Filippo Spriano, Ivo Kwee, Alberto J. Arribas, Andrea Rinaldi, Thibaud Jourdan, Melanie Berthold, Andrea Sturz, Carolyn Sperl, Francesco Margheriti, Lorenzo Scalise, Giuseppe Gritti, Davide Rossi, Anastasios Stathis, Ningshu Liu, Emanuele Zucca, Oliver Politz, Francesco Bertoni
Journal: Blood Advances
Blood Adv (2020) 4 (5): 819–829.
https://doi.org/10.1182/bloodadvances.2019000844
Published: 2020
Includes: Supplemental data
Journal Articles

Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies

Melissa A. Fischer, Sharon Y. Friedlander, Maria P. Arrate, Hua Chang, Agnieszka E. Gorska, Londa D. Fuller, Haley E. Ramsey, Trinayan Kashyap, Christian Argueta, Sophie Debler, Michael Byrne, Matthew T. Villaume, Aaron C. Shaver, William Senapedis, Yosef Landesman, Erkan Baloglu, Sharon Shacham, Michael R. Savona
Journal: Blood Advances
Blood Adv (2020) 4 (3): 586–598.
https://doi.org/10.1182/bloodadvances.2019000359
Published: 2020
Includes: Supplemental data
Journal Articles

Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia

Victoria M. Smith, Oliver Lomas, Donna Constantine, Lianne Palmer, Anna H. Schuh, David Bruce, Oksana Gonchar, Salvador Macip, Sandrine Jayne, Martin J. S. Dyer, Toby A. Eyre
Journal: Blood Advances
Blood Adv (2020) 4 (3): 525–529.
https://doi.org/10.1182/bloodadvances.2019000917
Published: 2020
Includes: Supplemental data
Journal Articles

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

Clinical Trials & Observations
Thomas E. Lew, Mary Ann Anderson, Victor S. Lin, Sasanka M. Handunnetti, Neil A. Came, Piers Blombery, David A. Westerman, Meaghan Wall, Constantine S. Tam, Andrew W. Roberts, John F. Seymour
Journal: Blood Advances
Blood Adv (2020) 4 (1): 165–173.
https://doi.org/10.1182/bloodadvances.2019000864
Published: 2020
Includes: Supplemental data